Business
Advisory Board Appointment
Advisory Board Appointment.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 7662G Hemogenyx Pharmaceuticals PLC 06 March 2018 \n\nHemogenyx Pharmaceuticals Plc\n(\"Hemogenyx\" or the \"Company\")\n \nAdvisory Board Appointment\n \nHemogenyx appoints renowned cancer drug researcher to Advisory Board\nMichael Shepard brings experience in drug development, pharma collaborations\n \nHemogenyx Pharmaceuticals Plc. (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that H. Michael Shepard, Ph.D. has been appointed to the Company's Scientific Advisory Board. \n \nDr. Shepard is a pioneer in modern cancer research. His work has led to the discovery and development of many successful cancer treatments including Herceptin/trastuzumab, an antibody used to treat breast cancer patients. Sales of Herceptin and its biosimilars currently exceed $6.5 billion worldwide. \n \nIn 2006, Dr. Shepard received Harvard Medical School's prestigious Warren Alpert Prize in recognition of contributions to the field of cancer treatment research.\n \nIn his Advisory Board role, Dr. Shepard will draw on his many years of experience advancing antibody-based therapeutics from the development phase, through clinical studies and FDA approval, to commercial launch. He will use his expertise to advise Hemogenyx on the pre-clinical and clinical development of its lead candidate CDX antibodies. These highly specific CDX antibodies selectively eliminate hematopoietic stem cells and progenitors and a subset of acute myelogenous leukemia (AML), and promise to offer safer alternatives to chemotherapy and radiation as means of eliminating refractory/relapsed AML and patient conditioning before bone marrow transplants.\n \nCommenting Dr. Shepard, said: \"Hemogenyx is developing cancer therapies that have the potential to save lives, and I'm proud to be a part of that. As a member of Hemogenyx's Scientific Advisory Board, I'll be able to use the experience I've accrued working with other pre-clinical biotechnology programmes to help guide Hemogenyx toward the release of successful antibody-based therapies.\" \n \nDr. Vladislav Sandler, CEO of Hemogenyx, said: \"Hemogenyx has always sought out experienced experts with extensive biotech and large pharm...